Ionis Pharmaceuticals Financial Statements (IONS)
|
|
|
|
Report date
|
|
|
02.03.2020 |
24.02.2021 |
25.02.2022 |
22.02.2023 |
21.02.2024 |
|
06.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
1 123 |
729.0 |
810.0 |
587.0 |
787.6 |
|
803.1 |
|
Operating Income, bln rub |
|
|
366.0 |
-172.0 |
-30.0 |
-411.0 |
-353.7 |
|
-370.4 |
|
EBITDA, bln rub |
? |
|
411.5 |
-107.9 |
-0.239 |
-227.8 |
-230.0 |
|
-252.6 |
|
Net profit, bln rub |
? |
|
294.0 |
-487.0 |
-29.0 |
-270.0 |
-366.3 |
|
-358.8 |
|
|
OCF, bln rub |
? |
|
345.7 |
35.9 |
30.8 |
-274.4 |
-307.5 |
|
-351.9 |
|
CAPEX, bln rub |
? |
|
36.3 |
41.0 |
17.9 |
20.1 |
28.0 |
|
33.0 |
|
FCF, bln rub |
? |
|
309.4 |
-5.16 |
12.9 |
-294.5 |
-335.5 |
|
-373.4 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
753.0 |
889.0 |
829.0 |
984.0 |
779.6 |
|
1 152 |
|
Cost of production, bln rub |
|
|
4.00 |
12.0 |
11.0 |
14.0 |
9.13 |
|
21.7 |
|
R&D, bln rub |
|
|
466.0 |
535.0 |
643.0 |
833.0 |
899.6 |
|
912.6 |
|
Interest expenses, bln rub |
|
|
49.0 |
45.0 |
4.30 |
8.12 |
0.000 |
|
85.4 |
|
|
Assets, bln rub |
|
|
3 233 |
2 390 |
2 612 |
2 534 |
2 990 |
|
3 081 |
|
Net Assets, bln rub |
? |
|
1 471 |
843.0 |
772.0 |
573.0 |
386.7 |
|
662.5 |
|
Debt, bln rub |
|
|
710.0 |
749.0 |
1 161 |
1 345 |
1 454 |
|
1 447 |
|
Cash, bln rub |
|
|
2 500 |
1 892 |
2 115 |
1 987 |
2 331 |
|
2 483 |
|
Net debt, bln rub |
|
|
-1 790 |
-1 143 |
-954.0 |
-642.0 |
-877.7 |
|
-1 037 |
|
|
Ordinary share price, rub |
|
|
60.4 |
56.5 |
30.4 |
37.8 |
50.6 |
|
43.7 |
|
Number of ordinary shares, mln |
|
|
140.0 |
139.6 |
141.0 |
141.8 |
143.2 |
|
148.6 |
|
|
Market cap, bln rub |
|
|
8 457 |
7 894 |
4 291 |
5 358 |
7 244 |
|
6 498 |
|
EV, bln rub |
? |
|
6 667 |
6 751 |
3 337 |
4 716 |
6 366 |
|
5 461 |
|
Book value, bln rub |
|
|
1 445 |
815 |
743 |
573 |
387 |
|
662 |
|
|
EPS, rub |
? |
|
2.10 |
-3.49 |
-0.21 |
-1.90 |
-2.56 |
|
-2.41 |
|
FCF/share, rub |
|
|
2.21 |
-0.04 |
0.09 |
-2.08 |
-2.34 |
|
-2.51 |
|
BV/share, rub |
|
|
10.3 |
5.84 |
5.27 |
4.04 |
2.70 |
|
4.46 |
|
|
EBITDA margin, % |
? |
|
36.6% |
-14.8% |
-0.03% |
-38.8% |
-29.2% |
|
-31.5% |
|
Net margin, % |
? |
|
26.2% |
-66.8% |
-3.58% |
-46.0% |
-46.5% |
|
-44.7% |
|
FCF yield, % |
? |
|
3.66% |
-0.07% |
0.30% |
-5.50% |
-4.63% |
|
-5.75% |
|
ROE, % |
? |
|
20.0% |
-57.8% |
-3.76% |
-47.1% |
-94.7% |
|
-54.2% |
|
ROA, % |
? |
|
9.09% |
-20.4% |
-1.11% |
-10.7% |
-12.3% |
|
-11.6% |
|
|
P/E |
? |
|
28.8 |
-16.2 |
-148.0 |
-19.8 |
-19.8 |
|
-18.1 |
|
P/FCF |
|
|
27.3 |
-1 531 |
332.7 |
-18.2 |
-21.6 |
|
-17.4 |
|
P/S |
? |
|
7.53 |
10.8 |
5.30 |
9.13 |
9.20 |
|
8.09 |
|
P/BV |
? |
|
5.85 |
9.68 |
5.78 |
9.35 |
18.7 |
|
9.81 |
|
EV/EBITDA |
? |
|
16.2 |
-62.6 |
-13 963 |
-20.7 |
-27.7 |
|
-21.6 |
|
Debt/EBITDA |
|
|
-4.35 |
10.6 |
3 992 |
2.82 |
3.82 |
|
4.10 |
|
|
R&D/CAPEX, % |
|
|
1 284% |
1 303% |
3 592% |
4 144% |
3 212% |
|
2 764% |
|
|
CAPEX/Revenue, % |
|
|
3.23% |
5.63% |
2.21% |
3.42% |
3.56% |
|
4.11% |
|
| Ionis Pharmaceuticals shareholders |
